See the DrugPatentWatch profile for lurbinectedin

After an extensive search, I was unable to find specific information on which tests monitor Lurbinectedin's late side effects. Lurbinectedin is an antineoplastic agent, a type of drug used in cancer treatment [1]. Common side effects of antineoplastic agents include anemia, neutropenia, thrombocytopenia, nausea, and vomiting [1].

However, it is essential to monitor patients undergoing cancer treatment for potential late side effects. These may include cardiovascular, neurological, and secondary malignancies [2]. Therefore, tests to monitor these potential side effects may include, but are not limited to, cardiac function tests, neurological assessments, and imaging studies [2].

It is crucial to consult the prescribing information or a healthcare professional for specific information regarding Lurbinectedin's side effects and monitoring [1]. Additionally, DrugPatentWatch.com may provide information on Lurbinectedin's patents and clinical trials, which could offer further insight into its side effects and monitoring [3].

In summary, while there is no specific information on tests to monitor Lurbinectedin's late side effects, general tests to monitor potential late side effects of antineoplastic agents include cardiac function tests, neurological assessments, and imaging studies. Consult the prescribing information or a healthcare professional for specific information.

Sources:
[1] Lurbinectedin (PM01183) - DrugBank. (n.d.). Retrieved from https://go.drugbank.com/drugs/DB12057
[2] Late effects of cancer treatment. (2021, April 22). Mayo Clinic. Retrieved from https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/late-effects-of-cancer-treatment/art-20047175
[3] Lurbinectedin. (n.d.). DrugPatentWatch.com. Retrieved from https://www.drugpatentwatch.com/drugs/lurbinectedin